Exscien’s Fusion Protein

  1. Penetrates cell
  2. Accesses mitochondria
  3. Repairs mt-DNA

Exscien’s three-part fusion protein reverses conditions that have been clinically irreversible until now

The success of Exscien’s fusion protein in pre-clinical trials has far exceeded expectations. Until now, there have been no effective drug therapies to address the consequences resulting from Reactive Oxygen Species (ROS) induced damage. Pre-clinical tests conducted by leading independent researchers worldwide, in fields ranging from breast cancer to heart disease, have resulted in published studies that validate the potential of Exscien to radically transform oxidative disease research and treatment.
See examples of collaborative studies.

How our patented fusion protein works

We call Exscien1 a fusion protein because it is a synthesis of three functional components. The first is a TAT-based peptide that allows entry into the cell. The second is a mitochondrial targeting sequence which enables penetration of the mitochondrial membrane. Once inside the mitochondria, the third element repairs various lesions in DNA. It cleaves out the damaged nucleotides of mt DNA and inserts correct ones. It’s like performing cell surgery.

Harnessing nature’s own mechanisms to control and repair disease pathways

Essentially, Exscien has found a way to enhance the body’s natural healing mechanisms. Heart attacks, stroke, cancer, diabetes, Alzheimer’s and other countless chronic diseases are all caused by extensive oxidative damage in organs and tissues initiating changes at the molecular level. When the amount of destruction inflicted by ROS on mtDNA exceeds the cell’s natural coping mechanisms, Exscien allows the cell to regain its normal functionality. So far, there have been no treatments to address mitochondrial damage from ROS.

Exscien’s novel platform technology introduces and employs naturally occurring DNA repair enzymes at the point and time of oxidative stress. This allows the cell to cope with the accumulated damage and restores its normal function. Results of pre-clinical trials, both in vitro and in various animal models, have demonstrated efficacy in a wide range of chronic diseases and traumatic conditions. The findings have been nothing less than astounding, promising to re-invent the game for potential treatments of conditions (not just symptoms) that have been irreversible until now.
References: publications